Switching to aflibercept in patients with neovascular AMD not responding to anti-VEGF treatment.

Radboud University Nijmegen Medical Centre0 个研究点目标入组 20 人开始时间: 2013年5月17日最近更新: 2021年3月17日

适应症

试验速览

暂无简介。

•- Patients will have received at least 6 anti-VEGF injections within 1 year.
•- Active neovascular AMD seen as leakage on FA and (sub-) retinal fluid on OCT.
•- Maximally 1 year since onset of visual complaints and start of anti-VEGF treatment.
•- Minimally 1 month and maximally 3 months between last anti-VEGF injection and first aflibercept injection.
•- Age 50 years and older
•- Visual acuity at baseline between 20/25 and 20/320.
•- OCT available prior to first injection and after every three anti-VEGF injections.
•- Give written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•- Signs of subretinal fibrosis, scarring or geographic atrophy on OCT or FA, involving the center of the macula.
•- Pigment epithelial detachment with a maximum height of =150µm.
•- Any ocular diseases beside AMD in the study eye, including myopic fundus and vitreoretinal traction.
•- Myopia of 8.00 D or more, irrespective of myopic fundus features.
•- Ocular surgery of the study eye = 2 months prior to or during the previous anti-VEGF treatment.

发起方

Radboud University Nijmegen Medical Centre